Table I.
Patients’ characteristics.
| MRONJ (N = 15) | Non-MRONJ (N = 15) | Control (N = 15) | P-value | |
|---|---|---|---|---|
| Average age (SD) | 73.7 ± 7.8 | 73.3 ± 10.4 | 72.8 ± 5.9 | NS |
| Gender (male/female) | 3/12 | 3/12 | 3/12 | |
| Primary disease | ||||
| Osteoporosis | 9 | 11 | ||
| Breast cancer | 3 | 1 | ||
| Lung cancer | 2 | 2 | ||
| Prostate cancer | 1 | - | ||
| Rheumatoid arthritis | - | 1 | ||
| Medication | ||||
| Bisphosphonate Oral | ||||
| Alendronate | 5 | 8 | ||
| Risedronate | 4 | 3 | ||
| Minodronate | - | 1 | ||
| Intravenous | ||||
| Zoledronate | 4 | 3 | ||
| Denosumab | 1 | - | ||
| Denosumab and zoledronate | 1 | - | ||
| Administration duration (months) | ||||
| Average (SD) | ||||
| Bisphosphonate Oral | 20.4 ± 14.2 | 35.7 ± 34.4 | NS | |
| Intravenous | 18 ± 11.3 | 31.0 ± 1.6 | NS | |
| Denosumab | 3 | - | ||
| Denosumab and zoledronate | 15 | - | ||
| Administration period (No. of patients) | ||||
| < 3 years | 11 | 12 | ||
| ≥ 3 years | 4 | 3 | ||
| MRONJ site (No. of patients) | ||||
| Anterior mandible | 5 | |||
| Posterior mandible | 10 | |||
| MRONJ stage (No. of patients) | ||||
| 0 | 2 | |||
| 1 | 3 | |||
| 2 | 6 | |||
| 3 | 4 | |||
MRONJ = medication-related osteonecrosis of the jaw. ANOVA to compare 3 groups and unpaired t-test to compare 2 groups were performed. Data are presented as mean and standard deviation. P < 0.05 was considered statistically significant.